J07BC01 - Hepatitis B, Purified Antigen |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the hepatitis B, purified antigen vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Hepatitis B surface antigen
Therapeutic characteristics
The vaccine is indicated for the active immunization of adults, children and infants against hepatitis B. It is administered by intramuscular injections according to a three or four dose schedule.
Metabolism and pharmakokinetics
The hepatitis vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
References
- Government bodies
- Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). HBVAXPRO. (Last edition: March 2014). #1875
Similar drugs
© NAPOS 2024